Financial Performance - The company's operating revenue for Q1 2022 was RMB 394,174,107.03, representing a year-on-year increase of 7.50%[6] - The net profit attributable to shareholders of the listed company was RMB 35,823,760.85, showing a decrease of 21.36% compared to the same period last year[6] - The basic and diluted earnings per share were both RMB 0.08, reflecting a decline of 20.00% year-on-year[6] - Net profit for Q1 2022 was approximately RMB 36.25 million, a decrease of 20.9% from RMB 45.81 million in Q1 2021[34] - The total equity attributable to shareholders decreased to approximately RMB 3.42 billion in Q1 2022 from RMB 3.46 billion in Q1 2021, a decline of 1.2%[32] - The total comprehensive income attributable to the parent company was -42,619,357.36 CNY, compared to 198,663,061.28 CNY in the previous year, indicating a significant decline[37] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 38.83% to RMB 30,064,712.75, primarily due to increased procurement costs and higher performance bonuses paid to employees[11] - The net cash flow from operating activities was 30,064,712.75 CNY, down from 49,151,166.35 CNY year-over-year, reflecting a decrease of approximately 38.9%[41] - Cash received from the sale of goods and services was 395,390,920.90 CNY, an increase of 4.1% from 380,293,037.07 CNY in the previous year[41] - The total cash outflow from operating activities was 372,444,440.55 CNY, compared to 337,776,132.89 CNY in the previous year, reflecting an increase of approximately 10.2%[41] - The cash outflow from financing activities was 8,739,581.93 CNY, compared to 2,489,757.56 CNY in the previous year, indicating a significant increase in cash outflow[43] - The net cash flow from investment activities was -24,442,765.20 CNY, an improvement from -69,072,037.84 CNY in the previous year, showing a reduction in cash outflow from investments[41] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5,042,570,476.68, a slight increase of 0.18% from the end of the previous year[9] - The company's total liabilities increased to approximately RMB 1.55 billion in Q1 2022 from RMB 1.50 billion in Q1 2021, reflecting a growth of 3.7%[30] - As of March 31, 2022, the total current assets amounted to RMB 2,083,470,848.81, an increase from RMB 2,030,210,899.72 at the end of 2021[27] - The company's non-current assets totaled RMB 2,959,099,627.87, down from RMB 3,003,166,772.38 at the end of 2021[27] - The company's accounts receivable increased to RMB 498,494,250.32 from RMB 456,387,269.65 at the end of 2021, reflecting a growth of approximately 9.1%[27] - The company reported a decrease in cash and cash equivalents to RMB 1,190,853,808.99 from RMB 1,195,655,271.02 at the end of 2021[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 38,735[14] - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares, amounting to 56,787,503 shares[14] Investments and Agreements - The company invested RMB 20 million in Shanghai Zhongyuan Jisheng Cell Technology Co., holding a 50% equity stake after the capital increase[19] - The company signed a real estate lease agreement with Shanghai Yanlan Biotechnology Co., with an annual rent of RMB 7,256,784 for a 5,232 square meter property[22] - The total rental payment after discounts is RMB 60,956,985.60, with the first payment of RMB 17,960,540.40 due initially[22] Research and Development - Research and development expenses for Q1 2022 were approximately RMB 29.03 million, slightly down from RMB 29.77 million in Q1 2021[32] Other Financial Metrics - Non-recurring gains and losses totaled RMB 379,000.08 for the period, with government subsidies contributing RMB 273,114.23[10] - The weighted average return on net assets was 1.04%, a decrease of 0.26 percentage points compared to the previous year[6] - The company's deferred income tax liabilities were approximately RMB 34.12 million in Q1 2022, slightly down from RMB 34.70 million in Q1 2021[30] - The total comprehensive income for Q1 2022 included a significant other comprehensive loss of approximately RMB 78.44 million, contrasting with a gain of RMB 153.11 million in Q1 2021[34] - The company's cash and cash equivalents were not explicitly stated but are implied to be part of the overall financial health reflected in the total assets of approximately RMB 5.04 billion[32] - The company reported a credit impairment loss of approximately RMB 5.32 million in Q1 2022, compared to RMB 6.07 million in Q1 2021, indicating an improvement[34]

Financial Performance - The company's operating revenue for Q3 2021 was ¥391,700,257.34, representing an increase of 11.95% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2021 was ¥80,118,557.13, reflecting a significant increase of 54.74% year-over-year[7]. - The basic earnings per share for Q3 2021 was ¥0.17, up by 54.55% year-over-year[10]. - Net profit for the third quarter of 2021 was ¥194,586,517.04, compared to ¥133,093,977.65 in the previous year, indicating a growth of 46.1%[33]. - The company reported a profit before tax of ¥259,681,320.22, up from ¥170,448,436.72, representing a growth of 52.2%[33]. - Total comprehensive income for the period was CNY 186,621,508.15, a decrease from CNY 283,669,410.36 in the previous period[35]. - Basic and diluted earnings per share increased to CNY 0.41 from CNY 0.28 year-over-year[35]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,180,605,540.72, an increase of 6.17% from the end of the previous year[10]. - The total assets of the company were reported at ¥5,180,605,540.72, an increase from ¥4,879,569,536.17 year-over-year[24]. - Current liabilities totaled ¥1,382,441,046.85, compared to ¥1,300,015,430.19 in the previous year, showing an increase of approximately 6.3%[24]. - The company's total liabilities increased to ¥1,493,581,632.30 from ¥1,377,191,804.90, showing a rise of 8.4%[26]. - The total equity attributable to shareholders of the parent company rose to ¥3,586,855,067.12, up from ¥3,396,348,979.10, marking an increase of 5.6%[26]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥232,588,634.00, reflecting a year-over-year increase of 53.40%[10]. - Cash inflow from operating activities totaled CNY 1,245,397,088.82, up from CNY 1,060,592,301.77 in the previous year[39]. - Net cash flow from operating activities was CNY 232,588,634.00, compared to CNY 151,618,311.80 in the same period last year[39]. - Cash outflow from investment activities was CNY 164,292,903.89, significantly lower than CNY 735,223,631.40 in the previous year[39]. - Net cash flow from investment activities was negative CNY 92,456,340.77, compared to a positive CNY 306,040,337.65 in the previous year[39]. - Total cash inflow from financing activities was CNY 692,100.00, down from CNY 35,876,865.61 in the previous year[39]. - Net cash flow from financing activities was negative CNY 21,937,567.81, compared to negative CNY 72,575,923.72 in the previous year[39]. Shareholder Information - The company reported a total of 38,203 common shareholders at the end of the reporting period[14]. - The major shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares[14]. Investments and Expenses - Research and development expenses for the third quarter were ¥102,165,541.66, compared to ¥93,035,969.44 in the same quarter of 2020, reflecting a 9.1% increase[29]. - The company attributed the increase in net profit to the fair value gains from the fund shares held by its foreign subsidiary Aceso[13]. - Total operating costs amounted to ¥1,000,760,328.15, up from ¥857,674,929.78, reflecting a significant increase in expenses[29]. Other Financial Metrics - The weighted average return on equity for Q3 2021 was 2.22%, an increase of 0.79 percentage points compared to the same period last year[10]. - The deferred income tax liabilities increased significantly to ¥35,481,489.27 from ¥14,405,856.03, indicating a rise of 146.5%[26]. - The company recorded a decrease in other comprehensive income after tax, amounting to -¥7,965,008.89, compared to an increase of ¥150,575,432.71 in the previous year[33]. - The company reported a decrease in inventory, which stood at ¥217,958,041.29, down from ¥222,395,516.19[21]. - The company's goodwill remained stable at ¥722,634,814.15, unchanged from the previous year[24].

公司代码：600645 公司简称：中源协和 2021 年半年度报告 中源协和细胞基因工程股份有限公司 2021 年半年度报告 1 / 145 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王勇、主管会计工作负责人王鹏及会计机构负责人（会计主管人员）王鹏声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意投资风 险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已经在本报告中详细描述了公司存在的风险因素，敬请查阅第三节 ...

证券代码：600645 证券简称：中源协和 公告编号：2021-018 中源协和细胞基因工程股份有限公司 关于举行"投资者网上集体接待日"活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●召开时间：2021年5月19日（星期三）15:00-16:30 ●召开方式：网络方式召开 ● 投 资 者 在 接 待 日 活 动 召 开 前 登 录 全 景 网 互 动 平 台 中 源 协 和 页 面 （https://ir.p5w.net/c/600645.shtml）进行提问，或在召开当天15:00-16:30 登录"全景·路演天下"（http://rs.p5w.net）参与本次互动交流。 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2021年4月24 日发布了2020年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在全景网以网络方式举行"投资者网上集体接待日"活动。 二、召开时间和方式 时间：2021年5月19日（星期三）15:00-16:30 方式：网络方式召开 ...

Financial Performance - In 2020, the company's operating revenue was approximately RMB 1.32 billion, a decrease of 4.90% compared to RMB 1.39 billion in 2019[25]. - The net profit attributable to shareholders of the listed company for 2020 was a loss of approximately RMB 126.86 million, a decline of 355.29% compared to a profit of RMB 49.69 million in 2019[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of approximately RMB 211.75 million, a decrease of 844.60% compared to a profit of RMB 28.44 million in 2019[25]. - Basic earnings per share for 2020 was -0.27 yuan, a decrease of 345.45% compared to 2019[26]. - Net profit attributable to shareholders decreased by 355.29% year-on-year, primarily due to a goodwill impairment loss of 265 million yuan[26]. - The company reported a cumulative undistributed profit of approximately RMB -227 million as of December 31, 2020, leading to no profit distribution to shareholders[6]. - The company has indicated that it will not implement capital reserve transfers to increase share capital or other forms of distribution due to the negative cumulative undistributed profit[6]. - The company reported a net profit margin of 0% for the years 2018, 2019, and 2020, indicating no profit distribution to shareholders[121]. Cash Flow and Investments - The net cash flow from operating activities for 2020 was approximately RMB 244.35 million, an increase of 1.19% compared to RMB 241.49 million in 2019[25]. - The company’s cash and cash equivalents increased by 67.85% compared to the beginning of the period, primarily due to the maturity of structured deposits[50]. - The company reported a significant improvement in cash flow from investment activities, with a net cash inflow of 308.09 million RMB, compared to a net outflow of 555.14 million RMB in the previous year[68]. - Cash flow from investing activities saw a significant increase of 155.50%, totaling ¥308,090,854.44, primarily due to the maturity of structured deposits[85]. - The company recognized an investment income of ¥43,300,143.33 from its subsidiary's investment in Aceso Biotech Venture Fund[87]. Business Operations and Strategy - The company operates in the "precision medicine" industry, focusing on cell detection preparation and storage, in vitro diagnostic materials, and gene testing services[36]. - The company has established cell resource banks across over 2/3 of the regions and 3/4 of the population in China, providing extensive coverage for stem cell detection and preparation services[36]. - The company has diversified its business model to include both newborn and adult cell storage services, catering to health-conscious adults and research institutions[36]. - The company aims to enhance its core businesses in cell storage and in vitro diagnostic reagents, focusing on expanding product lines and increasing R&D investment[111]. - The company will continue to enrich its cell storage offerings, including various types of stem cells and immune cells, while expanding its diagnostic testing products[111]. - The company is committed to promoting the clinical application of cell therapies and advancing related product development in collaboration with top-tier hospitals[111]. Research and Development - The company continued to invest in R&D, with R&D expenses increasing by 4.36% to 114.43 million RMB, reflecting a commitment to sustainable business growth[68]. - The company launched 18 self-developed projects in the in vitro diagnostic business, obtaining 19 registration certificates, indicating a strong focus on innovation[67]. - The number of R&D personnel increased to 174, accounting for 7.79% of the total workforce[83]. - The company completed 18 out of 42 major stem cell research and product development projects during the reporting period[84]. Market and Industry Trends - The domestic in vitro diagnostic industry is experiencing significant growth, driven by factors such as population aging and rising cancer incidence[43]. - The government has been actively promoting policies to support the development of the stem cell industry, indicating a favorable environment for growth[43]. - The "14th Five-Year Plan" emphasizes biotechnology as a strategic emerging industry, aiming to strengthen the bio-economy and optimize resource allocation for innovation[110]. Risk Factors and Compliance - The company has detailed risk factors that it may face in the report, which investors should review carefully[8]. - The company faces potential risks from industry policies, technology advancements, talent retention, and currency fluctuations, which could impact its operations and financial performance[117]. - The company has established a commitment to fair and transparent governance practices in all related transactions[139]. Environmental Responsibility - The company has implemented a self-monitoring plan for environmental emissions, ensuring compliance with pollution discharge standards[186]. - The company has established an emergency response plan for environmental incidents to minimize potential damage and ensure public safety[185]. - The company’s wastewater discharge met the standards with COD at 96 mg/L, significantly below the limit of 500 mg/L, and no exceedances reported[182]. Shareholder Relations and Commitments - The company has not distributed profits for 2019 and 2020 due to accumulated losses, with a net profit of 6.33 million yuan in 2020[120]. - The company has committed to not engaging in any business that competes with its subsidiaries, ensuring no direct or indirect competition[126]. - The company has established a commitment to avoid any illegal occupation of funds or assets, ensuring compliance with relevant laws and regulations[142].

Financial Performance - Net profit attributable to shareholders increased by 644.70% to CNY 45,553,625.54 year-on-year[12] - Operating revenue rose by 32.44% to CNY 366,683,497.82 compared to the same period last year[12] - Basic and diluted earnings per share both reached CNY 0.10, up 900.00% from CNY 0.01 in the previous year[12] - The significant increase in net profit was primarily due to the full waiver of the "PPP loan" approved by the SBA during the reporting period[18] - The net profit for Q1 2021 was ¥45,810,334.85, compared to a net profit of ¥5,889,050.84 in Q1 2020, representing a significant increase[45] - The comprehensive income total for Q1 2021 was ¥198,919,770.59, compared to ¥12,329,379.82 in Q1 2020, indicating strong growth[45] Cash Flow - Net cash flow from operating activities surged by 1,491.49% to CNY 49,151,166.35 year-on-year[12] - Cash flow from operating activities for Q1 2021 was ¥49,151,166.35, a significant increase from ¥3,088,365.70 in Q1 2020[55] - The net cash flow from operating activities for Q1 2021 was -8,926,947.28 RMB, an improvement from -20,879,853.57 RMB in Q1 2020[57] - Total cash inflow from operating activities was 58,829,999.63 RMB, compared to 46,385,745.41 RMB in the same period last year, representing a 26.8% increase[57] Assets and Liabilities - Total assets increased by 5.05% to CNY 5,126,007,661.74 compared to the end of the previous year[12] - Total liabilities reached ¥1,424,710,159.88, up from ¥1,377,191,804.90, marking a growth of around 3.44%[33] - Current liabilities rose to ¥1,324,843,654.87, compared to ¥1,300,015,430.19, indicating an increase of approximately 1.91%[31] - The company’s long-term borrowings decreased by 28.56% compared to the beginning of the year, due to the full exemption of previously applied loans[22] - The total assets as of Q1 2021 amounted to 4,879,569,536.17 RMB, a decrease from 4,935,894,374.98 RMB in the previous year[61] Shareholder Information - The number of shareholders at the end of the reporting period was 35,892[15] - The total equity attributable to shareholders increased to ¥3,595,012,040.38 from ¥3,396,348,979.10, reflecting a growth of about 5.85%[33] Expenses - Sales expenses increased by 47.93% year-on-year, mainly due to increased operating income during the reporting period[25] - Financial expenses decreased significantly by 1053.00% year-on-year, primarily due to increased interest income from deposits[25] - Research and development expenses for Q1 2021 were ¥29,769,464.49, slightly up from ¥27,897,123.35 in Q1 2020[44] Government Support - The company received government subsidies amounting to CNY 13,133,781.52, which are included in the current profit and loss[15] - Other income increased by 1690.68% year-on-year, mainly due to the full exemption of the "U.S. PPP Guarantee Program Loan" approved by the SBA[25] Investment Activities - Investment activities generated a net cash outflow of approximately 69.07 million, a decrease of 191.29% year-on-year, mainly due to structural deposits[28] - The company reported investment income losses of ¥2,564,779.24 in Q1 2021, compared to a gain of ¥2,314,299.99 in Q1 2020, indicating a downturn in investment performance[50] Changes in Financial Position - Other receivables increased by 142.83% to CNY 68,566,787.22 compared to the beginning of the year[19] - Other receivables rose significantly to ¥173,528,094.16 from ¥131,063,690.60, indicating an increase of approximately 32.5%[37] - Cash and cash equivalents decreased to ¥449,653,162.93 from ¥486,133,836.39, a decline of approximately 7.51%[33]

Financial Performance - The company reported operating revenue of RMB 969.37 million for the first nine months of 2020, a decrease of 3.58% compared to the same period last year[18]. - Net profit attributable to shareholders of the listed company reached RMB 133.10 million, an increase of 42.35% year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 52.73 million, down 26.42% from the previous year[18]. - Total operating revenue for Q3 2020 was CNY 349,874,853.88, a 3% increase from CNY 337,027,026.17 in Q3 2019[53]. - Net profit for Q3 2020 reached CNY 52,393,785.04, compared to CNY 32,194,645.05 in Q3 2019, representing a 62.7% increase[57]. - The total comprehensive income for the first three quarters of 2020 was CNY 133,093,977.65, up from CNY 104,980,318.52 in the same period of 2019[57]. - The total comprehensive income attributable to the parent company's owners for the current period is CNY 23,534,610.23, compared to CNY 35,137,921.60 in the same period last year, reflecting a decrease of approximately 33.5%[60]. - The company reported a net loss of ¥450,885,928.09, an improvement from a loss of ¥583,988,877.39 in the previous period[44]. Assets and Liabilities - The total assets of the company at the end of the reporting period were RMB 5.13 billion, reflecting an increase of 4.85% compared to the end of the previous year[18]. - The company’s total equity attributable to shareholders was RMB 3.61 billion, an increase of 7.77% from the end of the previous year[18]. - Total current assets increased to ¥1,942,380,637.21 as of September 30, 2020, up from ¥1,905,868,878.58 on December 31, 2019, representing a growth of 1.9%[38]. - Total non-current assets reached ¥3,183,407,926.35, compared to ¥2,982,669,581.79, reflecting a growth of 6.7%[42]. - Total liabilities decreased slightly to ¥1,400,241,654.71 from ¥1,427,816,142.75, a reduction of 1.9%[44]. - The total cash and cash equivalents at the end of the period amounted to ¥1,010,203,787.47, compared to ¥990,675,535.57 at the end of the same period last year[71]. Cash Flow - The company generated a net cash flow from operating activities of RMB 151.62 million, a decrease of 3.24% compared to the same period last year[18]. - Net cash flow from investing activities increased by 394.26% compared to the same period last year, mainly due to the recovery of structured deposits[33]. - Net cash flow from financing activities decreased by 120.59% compared to the same period last year, primarily due to the absence of funds raised from a previous equity issuance[33]. - The net cash flow from operating activities for the first three quarters of 2020 was ¥151,618,311.80, a decrease from ¥156,699,220.70 in the same period of 2019[71]. - Cash inflow from investment activities reached ¥1,041,263,969.05, significantly higher than ¥16,764,934.16 in the previous year[71]. - The net cash flow from investment activities was ¥306,040,337.65, a recovery from a negative cash flow of ¥104,003,678.31 in the same period of 2019[71]. - The net cash flow from financing activities was -¥72,575,923.72, contrasting with a positive cash flow of ¥352,456,237.59 in 2019[71]. Shareholder Information - The number of shareholders at the end of the reporting period was 31,827[24]. - Shareholders' equity increased to ¥3,725,546,908.85 from ¥3,460,722,317.62, showing a growth of 7.7%[44]. - Basic earnings per share for the current period is CNY 0.11, an increase from CNY 0.07 in the previous quarter, while diluted earnings per share also stands at CNY 0.11[62]. Investment and Expenses - The company confirmed an investment income of RMB 50.07 million from its U.S. subsidiary's investment in Aceso Biotech Venture Fund, L.P.[27]. - Investment income increased by 527.13% compared to the same period last year, primarily due to the recognition of investment income from subsidiaries[32]. - Research and development expenses for Q3 2020 were CNY 38,377,550.11, a 42.6% increase from CNY 26,913,020.93 in Q3 2019[53]. - The company’s long-term investments in equity decreased to ¥213,491,419.30 from ¥220,661,067.04, a decline of 3.9%[38]. - The cash outflow for purchasing fixed assets and intangible assets was ¥75,168,226.98, an increase from ¥54,658,612.47 in the previous year[71]. Other Financial Metrics - The weighted average return on equity increased to 3.85%, up 0.67 percentage points from the previous year[18]. - Other comprehensive income increased by 326.86% compared to the beginning of the year, mainly due to the recognition of fair value changes of investments[31]. - The company reported a gross profit margin of approximately 13.2% for Q3 2020, compared to 11.5% in Q3 2019[53]. - The company experienced a foreign currency translation loss of CNY -15,800,337.66 in the current period, impacting overall comprehensive income[60]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[53]. - The company has not reported any net profit from the merged entity prior to the merger, indicating a focus on future growth opportunities[62]. Accounting Standards - The company implemented new revenue and leasing standards starting January 1, 2020, which are not expected to significantly impact revenue recognition or net profit[76]. - The company did not make retrospective adjustments to prior period financial statements under the new standards[77].

Financial Performance - The company achieved operating revenue of RMB 619.50 million, a decrease of 7.31% compared to the same period last year[21]. - The net profit attributable to shareholders was RMB 81.33 million, an increase of 28.82% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 23.59 million, a decrease of 53.81% compared to the previous year[21]. - The net cash flow from operating activities was RMB 84.58 million, down 9.49% from the same period last year[21]. - The total assets at the end of the reporting period were RMB 5.11 billion, an increase of 4.52% from the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were RMB 3.59 billion, an increase of 7.07% year-on-year[21]. - Basic earnings per share were RMB 0.17, up 21.43% from RMB 0.14 in the same period last year[22]. - The weighted average return on net assets was 2.37%, an increase of 0.13 percentage points compared to the previous year[22]. Investment and Acquisitions - The company recognized an investment income of RMB 50.07 million from its U.S. subsidiary and the acquisition of Zhongyuan Weikang[25]. - The company aims for global expansion through strategic investments and acquisitions, enhancing its operational efficiency and service capabilities[31]. - The company made a significant equity investment of ¥35 million in Heze Biotechnology, acquiring a 100% stake in stem cell storage technology services[61]. - The company reported a profit impact of ¥44.97 million from the sale of its entire stake in Hebecell Corp. to Aceso Biotech Venture Fund, L.P.[67]. - The company’s investment in Aceso Biotech Venture Fund, L.P. was ¥35.40 million, representing a 53.33% equity stake[63]. Research and Development - The company’s R&D expenses increased by 11.47% to ¥54.66 million from ¥49.03 million year-on-year, reflecting a commitment to innovation[47]. - The company has completed six clinical trial registrations for stem cell projects, showcasing its active involvement in advanced medical research[46]. - The company has initiated clinical trials for two new drugs in the immunotherapy sector, indicating progress in its precision treatment initiatives[46]. - The company has established a certain technological lead in cell preservation, separation, and extraction, with several patents obtained and pending, but must continuously invest in R&D to maintain its competitive edge[78]. Market Position and Strategy - The main business focuses on "precision medicine," covering cell detection, preparation, storage, and gene testing services, with significant contributions from stem cell applications[28]. - The company has established a comprehensive cell resource network, serving over 2/3 of the regions and 3/4 of the population in China, enhancing its market presence[31]. - The company emphasizes internal growth and integration of production, research, and sales to improve operational efficiency and innovation[33]. - The company has developed a digital marketing strategy leveraging new media platforms to enhance brand exposure and value[46]. - The company is actively promoting innovative marketing and product development strategies to ensure steady growth[34]. Financial Stability and Risks - The company's trading financial assets decreased by 25.18% to approximately 300.52 million yuan due to the maturity of structured deposits[38]. - Other equity investments increased by 54.00% to approximately 600.94 million yuan, primarily due to fair value changes from overseas investments[38]. - The company faces foreign exchange risks due to its global operations, with sales denominated in multiple currencies, which may impact future financial results[80]. - The company acknowledges the risk of talent shortages and turnover, implementing strategies such as equity incentives and performance-based compensation to align interests and retain key personnel[78]. - The company has committed to closely monitoring national policy developments and adjusting its business and product structures to mitigate potential impacts from regulatory changes[78]. Compliance and Governance - The company reported a significant focus on compliance with legal regulations and corporate governance, emphasizing the protection of minority shareholders' rights[96]. - The company guarantees that any necessary related party transactions will be conducted at fair market prices and in compliance with relevant laws and regulations[92]. - The company has established a framework to address any potential asset impairment issues related to the profit commitments made[89]. - The company has committed to avoiding any form of competition with its subsidiaries, ensuring no similar business activities are conducted that could harm shareholder interests[95]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 32,801[127]. - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 84,064,327 shares, representing 17.96% of total shares[127]. - The total number of shares held by the top ten shareholders includes significant pledges, with Tianjin Development Zone Deyuan Investment having 81,233,260 shares pledged[127]. - The report indicates that there were no changes in the controlling shareholder or actual controller during the reporting period[133]. Legal Matters - The company has ongoing significant litigation regarding the transfer of state-owned land use rights, with a judgment requiring Singapore Huide Investment Holdings Co., Ltd. to repay CNY 71.21 million[104]. - In a separate case, the company is pursuing enforcement of a civil mediation agreement for a share transfer payment of CNY 30 million, of which only CNY 1 million has been received to date, leaving a balance of CNY 29 million unpaid[104].

证券代码：600645 证券简称：中源协和 公告编号：2020-038 中源协和细胞基因工程股份有限公司 关于举行"投资者网上集体接待日"活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●召开时间：2020年6月10日（星期三）15:00-16:30 ●召开方式：网络方式召开 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2020年4月29 日发布了2019年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在全景网以网络方式举行"投资者网上集体接待日"活动。 二、召开时间和方式 时间：2020年6月10日（星期三）15:00-16:30 方式：网络方式召开 三、公司出席人员 公司出席本次"投资者网上集体接待日"活动的人员有：公司董事、总经理 王勇先生，副总经理、董事会秘书杨新喆先生，财务总监王鹏先生（如有特殊情 况，出席人员会有调整）。 四、投资者参加方式 投资者可以登录" 全景·路演天下"（http://rs.p5w.net）参与交流。 欢迎广大投资者积极参 ...

Financial Performance - Net profit attributable to shareholders decreased by 80.17% year-on-year, amounting to CNY 6,117,082.04, primarily due to a decline in revenue caused by the pandemic [19]. - Operating revenue for the period was CNY 276,875,463.42, representing a decrease of 13.82% compared to the same period last year [12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 2,343,106.78, a decrease of 92.33% year-on-year [12]. - Net profit for Q1 2020 was $5.89 million, a decline of 84.5% compared to $37.89 million in Q1 2019 [46]. - The total profit for Q1 2020 was $14.34 million, down 72.6% from $52.38 million in Q1 2019 [44]. - The total comprehensive income for the period was reported at -¥5,059,820.62, compared to -¥9,676,426.99 in the previous year, indicating an improvement in financial performance [55]. Cash Flow - The net cash flow from operating activities was CNY 3,088,365.70, down 39.01% from CNY 5,063,415.77 in the previous year [12]. - Net cash flow from operating activities decreased by 39.01% to 3,088,365.70 from 5,063,415.77, mainly due to reduced cash received from sales [26]. - In Q1 2020, the company reported a net cash flow from operating activities of ¥3,088,365.70, a decrease of 39.1% compared to ¥5,063,415.77 in Q1 2019 [55]. - Total cash inflow from operating activities was ¥305,374,759.16, down from ¥330,905,299.64 in the previous year, reflecting a decline of 7.7% [55]. - The net cash flow from financing activities improved by 26.58% to -13,757,596.89 from -18,738,301.82, as the repayment of loans decreased compared to the previous year [26]. - The net cash flow from financing activities was -4,367,079.95, compared to a positive cash flow of 529,894.61 in the previous period [59]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,878,884,727.41, a decrease of 0.20% compared to the end of the previous year [12]. - Total liabilities amounted to approximately ¥1,405.83 billion, a decrease of 1.5% from ¥1,427.82 billion in the previous period [39]. - Non-current liabilities decreased to 1,330,679,579.61 from 1,350,003,407.69, reflecting a reduction in short-term borrowings [32]. - The total current assets were ¥662.05 million, a decrease of 1.3% from ¥670.43 million [38]. - The total assets decreased slightly to ¥4,197.23 billion from ¥4,209.13 billion, a decline of 0.3% [39]. Equity and Earnings - Basic earnings per share were CNY 0.01, a decrease of 85.71% compared to CNY 0.07 in the previous year [12]. - The weighted average return on equity decreased by 93.00 percentage points to 0.18% [12]. - The total equity attributable to shareholders reached ¥3,366.26 billion, an increase from ¥3,353.70 billion, reflecting a growth of 0.4% [39]. - The company’s total equity reached ¥3,473.05 billion, an increase from ¥3,460.72 billion, reflecting a growth of 0.4% [39]. Expenses - Employee compensation payable decreased by 48.29% to CNY 28,429,704.00, mainly due to the payment of 2019 annual performance bonuses [21]. - Research and development expenses increased to $27.90 million in Q1 2020, up 16.4% from $23.99 million in Q1 2019 [44]. - The company experienced a decrease in sales expenses to $59.72 million in Q1 2020 from $64.30 million in Q1 2019, a reduction of 7.9% [44]. - The company’s financial expenses decreased significantly to $248.86 thousand in Q1 2020 from $2.64 million in Q1 2019, a decline of 90.6% [44]. Investments - Investment income rose by 126.98% to 1,415,829.71 from -5,246,871.58, attributed to gains from the disposal of financial assets [23]. - The company reported an investment income of $1.42 million in Q1 2020, a significant improvement from a loss of $5.25 million in Q1 2019 [44]. - The company received ¥400,588,000.00 from investment recoveries in Q1 2020, indicating strong investment performance [55]. Accounting Standards - The company implemented new revenue and leasing standards starting January 1, 2020, which are not expected to significantly impact revenue recognition or financial metrics [59]. - The company did not make any retrospective adjustments to prior financial statements due to the new accounting standards [60]. - The company’s total assets and net assets are not expected to be significantly affected by the new accounting standards [59].